The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - REMD Biotherapeutics
Leadership - REMD Biotherapeutics
Stock and Other Ownership Interests - REMD Biotherapeutics
Consulting or Advisory Role - ARMO BioSciences
A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
 
Manish A. Shah
Research Funding - Boston Biomedical (Inst); Gilead Sciences (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Eduardo Patricio Yanez Ruiz
No Relationships to Disclose
 
Gyorgy Bodoky
Consulting or Advisory Role - Bayer; Ipsen; Janssen; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Lilly; Novartis; Pfizer; Roche
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
David Cunningham
Research Funding - 4SC (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Sanofi (Inst)
 
Desmond Yip
Stock and Other Ownership Interests - CSL Behring; Healthscope Advanced Pathology; Sonic Healthcare
Consulting or Advisory Role - Eisai (Inst); Merck Serono (Inst); Pfizer (Inst); Seqirus (Inst)
Travel, Accommodations, Expenses - Novartis
 
Zev A. Wainberg
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis; Sirtex Medical
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Jacobio (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); TRACON Pharma (Inst); Tyrogenex (Inst)
 
Dung Thai
No Relationships to Disclose
 
Pankaj Bhargava
Employment - Gilead Sciences
Leadership - Tioma Therapeutics
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Dicerna
Patents, Royalties, Other Intellectual Property - AVEO; Sanofi
 
Jaffer A. Ajani
Honoraria - Aduro Biotech; Bristol-Myers Squibb; Lilly; Merck
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly